We are pleased to publish the report from the workshop on ‘Real world evidence’, held in partnership with the Academy of Medical Sciences.
The report summarises the presentations and discussions from the meeting, which highlighted the potential of real world evidence to significantly impact how medicines are evaluated. Over the course of the day, several barriers to realising this opportunity were identified by participants including a requirement for further clarity from regulators and HTA bodies on the acceptability of real world evidence, the need for coordination and leadership in this area to provide direction, a shift in perceptions of real world evidence and standardisation of data capture and analysis.
The workshop report can be downloaded here, and further information on the meeting can be found on the Academy's policy project page.
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK. Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases. The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
The Academy of Medical Sciences’ FORUM was established in 2003 and aims to catalyse connections across industry, academia and the healthcare sector. Since then, a range of FORUM activities and events have brought together researchers, research funders and research users from across academia, industry, government, and the charity, healthcare and regulatory sectors. Further information and details of future events can be found on the FORUM homepage.